Harvard Bioscience has entered into a merger agreement to acquire 100% of the outstanding stock of Data Sciences International (DSI) for approximately $70 million.   DSI,a life science research company, is a leader in physiologic monitoring focused on delivering preclinical products, systems, services and solutions to its customers. For the trailing 12 months ending December 31, 2017, DSI had approximately $44 million in revenue.   Harvard Bioscience expects the transaction to ge...